Context:

Melanoma risk arises from a mix of genetic predisposition, skin type, and UV exposure, with fair skin identified as a leading risk factor due to lower melanin protection. Emerging evidence highlights lifetime UVA exposure as a meaningful contributor to melanoma risk, challenging the UVB-centric focus of public messaging. Prognosis hinges on tumor thickness (Breslow depth) and ulceration, guiding surgical and sentinel node decisions. The decline in melanoma mortality since 2013 is largely linked to immune checkpoint inhibitors that bolster long-term survival in advanced cases. Public concerns about sunscreen components persist, as some ingredients like oxybenzone can appear in the bloodstream after a single use and may affect hormone synthesis.

Dive Deeper:

• Fair skin substantially elevates melanoma risk because it provides less natural protection against UV radiation, increasing UV-induced DNA damage and cancer risk.

• Recent large-scale cohorts indicate that high lifetime ambient UVA exposure raises melanoma risk even when UVB exposure is accounted for, highlighting the need to address UVA in prevention.

• Prognosis in cutaneous melanoma is most strongly influenced by Breslow thickness and ulceration, with thickness indicating deeper invasion and a higher chance of spread, influencing surgical margins and biopsy strategies.

• The most significant factor in the mortality decline since 2013 is the advent of immune checkpoint inhibitors, such as anti-PD-1 therapies, which have transformed outcomes for advanced melanoma.

• Oxybenzone, a common sunscreen filter, has been detected in the blood after a single application and is associated with potential hormonal effects, underscoring ongoing safety evaluations of sunscreen ingredients.